VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?
Key Points
VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI's 0.35%.
XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare sector.
VHT has demonstrated lower price volatility and a much milder maximum drawdown over the last five years.
The Vanguard Health Care ETF (NYSEMKT:VHT) offers broad sector exposure and lower fees, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a concentrated, more volatile play on the biotechnology subsector.
Investors looking for exposure to the medical field often weigh broad sector coverage against niche industry plays. This comparison examines how a diversified giant like VHT stacks up against a more volatile, subsector-focused option like XBI, highlighting differences in risk, cost, and portfolio concentration.
Snapshot (cost & size)
| Metric | XBI | VHT |
|---|---|---|
| Issuer | State Street | Vanguard |
| Share price (as of Sept. 22, 2026) | $162.30 | $320.51 |
| Expense ratio | 0.35% | 0.09% |
| 1-yr return (as of Sept. 22, 2026) | 66.3% | 25.2% |
| Dividend yield | 0.35% | 1.48% |
| Beta (5Y monthly) | 1.12 | 0.58 |
| Assets under management (AUM) | $11.4 billion | $22.0 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Cost-conscious investors may find VHT more appealing, as its 0.09% expense ratio is significantly lower than XBI's 0.35%. Furthermore, the Vanguard fund provides a more substantial income stream with a 1.48% dividend yield, compared to the 0.35% offered by its biotech-focused peer.
Performance & risk comparison
| Metric | XBI | VHT |
|---|---|---|
| Max drawdown (5 yr) | -63.9% | -17.7% |
| Growth of $1,000 over 5 years (total return) | $1,222 | $1,336 |
What's inside
VHT provides broad exposure to the U.S. healthcare sector, holding 416 stocks through a passive replication strategy. Its portfolio is 100% focused on healthcare companies, and its largest positions include Eli Lilly, Johnson & Johnson, and AbbVie. The fund was launched in 2004 and has paid $4.72 per share in dividends over the trailing 12 months.
XBI focuses specifically on the biotechnology industry, tracking its index through representative sampling. This approach results in a more concentrated portfolio of 165 holdings, with the largest positions in Twist Bioscience, Moderna, and Natera. The fund was launched in 2006 and has paid $0.57 per share in dividends over the trailing 12 months.
For more guidance on ETF investing, check out the full guide at this link.
Which looks like the better buy
VHT and XBI differ in their scope and diversification, which have had meaningful impacts on their risk profiles and performance.
VHT is the more diversified of the two, not just in terms of the number of stocks, but in its sector focus, too. Around 24% of the fund is allocated to biotechnology stocks, but it also provides exposure to pharmaceuticals, healthcare equipment, life sciences, and more.
XBI's more targeted approach has led to a substantially higher one-year total return, more than doubling VHT's performance. However, it's also experienced a much more severe max drawdown and a higher beta, suggesting greater short-term volatility.
Choosing between them will depend on the gaps you're looking to fill within your portfolio. XBI can provide targeted exposure specifically to biotechnology stocks as part of a well-diversified portfolio, while VHT offers broader access to the greater healthcare sector. Both ETFs can be smart choices, but the right one will depend on your unique situation.
Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, Moderna, Natera, and Twist Bioscience. The Motley Fool recommends Johnson & Johnson and SPDR Series Trust - SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.